For decades, SMAD7 had a reputation. It was an inhibitor, a brake pedal in the cellular signalling network, a protein whose job was to dampen down the TGF-beta pathway and keep tissue growth under control. That, at any rate, was the consensus. It turns out the consensus was wrong, or at least badly incomplete, and a team at Sichuan University in China has now shown that inside the nuclei of human dental pulp stem cells, SMAD7 is doing something quite the opposite.
The finding matters beyond dentistry. SMAD7’s molecular partner in this newly discovered role is beta-catenin, the central player in the Wnt signalling pathway, which governs cell proliferation across an enormous range of tissues: bone, hair follicles, gut lining, skeletal muscle. Anywhere Wnt goes, the story of SMAD7 is likely to be relevant.
Dental pulp is a good place to start asking these questions. The soft tissue at the core of a tooth contains a population of stem cells that, under the right conditions, can regenerate the dentin layer and keep a tooth biologically alive after trauma or decay. The catch is that those right conditions are genuinely difficult to engineer. Severe infection disrupts the pulp’s microenvironment, the natural repair signals get drowned out, and what remains is usually managed with conventional root canal treatment rather than anything that actually restores living tissue. Tian Chen and her colleagues at West China Hospital of Stomatology have been trying to understand why regeneration is so hard to reliably trigger, and which molecular levers might make it more predictable.
Their attention landed on SMAD7 because of an earlier peculiarity. When they knocked out the Smad7 gene in mice, the animals developed notably smaller molars. Not diseased molars, just smaller ones. Cell proliferation in the tooth germ was reduced.
Tracking the same question into human cells, the team established a knockdown system using lentiviral vectors that silenced SMAD7 expression in human dental pulp stem cells. The consequences were substantial: the cells divided more slowly, migrated less effectively, and showed significantly higher rates of apoptosis. When the silenced cells were encapsulated in treated dentin matrices and implanted subcutaneously into immunocompromised mice (a standard proxy for assessing dental regeneration potential), the results were similarly stark. Control cells laid down a recognisable layer along the dentin surface, something close to the odontoblast lining in a native tooth. The SMAD7-knockdown cells did not. The tissue just didn’t form.
“We were surprised to observe SMAD7 functioning as a positive regulator within the nucleus,” said Dr. Chen, a postdoctoral researcher in the Department of Orthodontics at West China Hospital of Stomatology. “This direct partnership with beta-catenin provides a clearer explanation for how Wnt signalling is amplified during dental pulp regeneration.”
The mechanism, once the team worked through it, has a certain elegance. In the canonical TGF-beta pathway, a set of proteins called SMAD2 and SMAD3 become phosphorylated and travel to the nucleus. They are, normally, the pathway’s messengers. What the Sichuan team found is that phosphorylated SMAD2/3 can also bind to beta-catenin in the cytoplasm, physically sequestering it and preventing it from reaching the nucleus where it would activate Wnt target genes. This is the indirect mechanism: SMAD7 suppresses SMAD2/3 activity, which frees beta-catenin from that cytoplasmic trap, which allows Wnt signalling to proceed. Knock out SMAD7, and SMAD2/3 accumulates, beta-catenin gets sequestered, and Wnt target genes go quiet. The cell proliferation markers (c-Myc, Cyclin-D1, Ki-67) drop across the board.
The direct mechanism is the one nobody was expecting. Using co-immunoprecipitation assays and a yeast two-hybrid screen (which tests for direct protein-protein contact in a living cell), the team showed that SMAD7 binds physically to beta-catenin and helps shuttle it into the nucleus. The two proteins co-localise there and appear to form a transcriptional complex, directly activating Wnt-responsive genes. Reduce SMAD7 and there is measurably less nuclear beta-catenin; reduce beta-catenin and there is measurably less nuclear SMAD7. The proteins appear to need each other to get where they are going.
It is worth noting what this study does not resolve. The specific Wnt target genes that the SMAD7/beta-catenin complex actually activates, and whether the complex selectively drives proliferation or differentiation depending on context, remain unknown. The researchers suggest that chromatin immunoprecipitation sequencing will be necessary to map those interactions properly. And the work stays in cell culture and mouse models; there are no patient data, no clinical trials, and a considerable distance between a mechanistic insight in stem cells and a treatment that reliably regenerates a damaged tooth.
Whether SMAD7 promotes or inhibits Wnt activity also appears to be tissue-dependent in ways that complicate any simple account. In skin, the same SMAD7/beta-catenin interaction leads to beta-catenin degradation and restricted hair follicle formation. In skeletal muscle, it promotes beta-catenin’s nuclear entry and drives differentiation. The Sichuan findings add dental pulp to the “promotes” column, but the picture across tissues is not uniform.
Still, the translational implications are fairly direct. The team were able to rescue SMAD7-knockdown cells in the dentin matrix model by administering a Wnt agonist called SKL-2001, which stabilises beta-catenin by blocking one of its degradation interactions. Cell content in the implanted matrices recovered, Ki-67 expression came back up, and the dentin-specific marker DSPP returned. That suggests the downstream pathway can be pharmacologically accessed even when SMAD7 expression is reduced. “Our motivation comes from clinical challenges we see every day,” Dr. Chen added. “Understanding these molecular interactions brings us closer to therapies that regenerate living tissue and transform restorative care.”
The longer arc of this research points somewhere rather larger than dentistry. Wnt/beta-catenin signalling runs through bone biology, craniofacial development, and a broad class of tissue engineering applications; a protein that can directly potentiate it by escorting beta-catenin into the nucleus is potentially a target across all of them. Whether small molecules designed to stabilise the SMAD7/beta-catenin complex could one day guide stem cell fate decisions in multiple tissue contexts, not just dental pulp, is the kind of question that tends to take a decade to answer properly.
DOI / Source: https://doi.org/10.1038/s41368-025-00393-5
Frequently Asked Questions
The short answer is that the biological conditions for regeneration are genuinely difficult to recreate. Dental pulp contains stem cells capable of laying down new dentin, but severe infection or inflammation disrupts the signalling environment those cells depend on. Root canal treatment is reliable in a way that biological repair currently isn’t, though research like this is trying to identify the specific molecular switches that would make regeneration more predictable.
It could be, though the path from molecular mechanism to clinical treatment is long. The Sichuan University team showed that activating the downstream Wnt pathway pharmacologically (using a compound called SKL-2001) rescued the regenerative function that SMAD7 loss had impaired. That suggests the signalling axis is druggable in principle; whether a safe, effective formulation could be delivered to damaged pulp tissue is a separate engineering problem that hasn’t been addressed yet.
Almost certainly. The SMAD7/beta-catenin interaction the team discovered isn’t unique to dental tissue; it operates within a signalling network that governs cell proliferation across bone, muscle, gut lining, and other tissues. Whether the same complex has the same pro-growth function in those contexts, or does something quite different (as it apparently does in skin), is an open question that other researchers will now be motivated to investigate.
It works through two routes simultaneously. Indirectly, SMAD7 suppresses a group of proteins (phosphorylated SMAD2/3) that would otherwise trap the key Wnt messenger protein beta-catenin in the cytoplasm, preventing it from reaching the nucleus. Directly, SMAD7 physically binds beta-catenin and appears to escort it into the nucleus, where the two proteins together activate Wnt target genes. The inhibitor label wasn’t entirely wrong; SMAD7 does inhibit TGF-beta signalling, but it turns out that inhibiting one pathway is precisely what enables another to run.
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.
Key Takeaways
- SMAD7 has been found to act as a positive regulator in dental pulp stem cells, contrary to its previous reputation as an inhibitor.
- It partners with beta-catenin to amplify Wnt signaling, crucial for tissue regeneration across various systems, not just dental.
- Research shows silencing SMAD7 leads to slower cell division, less effective migration, and lower regeneration potential.
- Pharmacological activation of the Wnt pathway can rescue signals lost with reduced SMAD7, indicating potential drug targets for tissue repair.
- The implications of this study extend beyond teeth, affecting broader areas like bone and muscle biology, and future research will be necessary to explore these connections.